GSK plc (LON:GSK)
1,802.00
+7.00 (0.39%)
Nov 26, 2025, 8:44 AM BST
GSK plc Revenue
GSK plc had revenue of 8.55B GBP in the quarter ending September 30, 2025, with 6.68% growth. This brings the company's revenue in the last twelve months to 32.17B, up 2.73% year-over-year. In the year 2024, GSK plc had annual revenue of 31.38B with 3.46% growth.
Revenue (ttm)
32.17B
Revenue Growth
+2.73%
P/S Ratio
2.24
Revenue / Employee
468.69K
Employees
68,629
Market Cap
72.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
GSK plc News
- 4 days ago - AnaptysBio Buckles After Trading Legal Barbs With Pharma Giant GSK - Investor's Business Daily
- 4 days ago - Why GSK (GSK) is a Top Value Stock for the Long-Term - Nasdaq
- 4 days ago - AnaptysBio (ANAB) Faces Legal Battle with GSK's Subsidiary Over Cancer Drug Agreement - GuruFocus
- 4 days ago - AnaptysBio (ANAB) Shares Plunge Amid Legal Battle with GSK - GuruFocus
- 4 days ago - AnaptysBio shares tumble after legal fight with GSK over cancer drug license - Reuters
- 4 days ago - GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties - Benzinga
- 4 days ago - GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties - Benzinga
- 4 days ago - AnaptysBio drops as litigation with GSK unit risks cancer therapy deal - Seeking Alpha